December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi Winthrop Industrie

< Previous 1 2 Next >
News headline image
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Myqorzo and Redemplo approved in China
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Availability of the Q4 2025 Aide memoire
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi completes acquisition of Vicebio
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Sanofi successfully prices USD 3 billion of bond issue
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Q3: continued sales and earnings progress
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
From Sanofi Winthrop Industrie
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.